sur DIAGNOSTIC MEDICAL (EPA:ALDMS)
DMS Group Reports Q2 2026 Revenue of €12.2 Million
DMS Group, specializing in medical imaging systems, reported a Q2 2026 revenue of €12.2 million, marking a 4% decrease compared to the previous year. The company faced challenges in the radiology sector due to global economic conditions and delayed equipment deliveries to Ukraine. Despite this, there was a notable rebound in the Bone Densitometry sector, with Q2 revenue up by 32% following a prior decline.
For H1 2026, DMS Group's revenue stood at €22.1 million, down 6% from H1 2025. The drop is attributed to deferred contracts and cautious spending trends, particularly in Europe. However, DMS anticipates a stronger second half, expecting an ease in geopolitical tensions and better economic conditions.
DMS Group confirmed its 2026 guidance, aiming to outperform the market amid economic and geopolitical challenges. Growth is expected mainly from international markets, especially North America, supported by strategic partnerships.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de DIAGNOSTIC MEDICAL